Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021


Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal fourth quarter and year-ended September 30, 2021 after the U.S. market closes on November 22, 2021. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, including its research and development pipeline.

Conference Call and Webcast Information

To participate in the live conference call, please dial 844-467-7101 in the U.S. or 270-215-9353 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 22, 2021, through 11:59 p.m. ET on November 29, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 1973737. A live audio webcast of the call and replay can be accessed by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 04:30
#PLAYTOINSPIRE -- Last night, GRAMMY® award-nominated, multi-platinum, and chart topping singer/songwriter Camila Cabello delivered a breath-taking performance live from the Stade de France in Paris, to fans around the world, at the UEFA Champions...

at 03:00
#PLAYTOINSPIRE -- Last night, GRAMMY® award-nominated, multi-platinum, and chart topping singer/songwriter Camila Cabello delivered a breath-taking performance live from the Stade de France in Paris, to fans around the world, at the UEFA Champions...

at 02:37
Resecurity®, a cybersecurity and intelligence company, showcased its next-generation cybersecurity platform at the 2022 MILIPOL Asia-Pacific (APAC) conference in Singapore. The MILIPOL APAC event welcomed over 7,000 government and law enforcement...

28 mai 2022
Cueto Law Group, an international business law firm based in Miami, Florida, represents plaintiffs against Operational and Financial Advisory LLC, a company tied to Evan Tromp. In the lawsuit, Operational and Financial Advisory, LLC. is being sued...

28 mai 2022
Unifor members at Bell Technical Solutions (BTS) voted to ratify a strong collective agreement that delivers significant improvements in benefits, RRSP contributions, and wages for members across Ontario....

28 mai 2022
Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, concluded a visit to Europe, where he met with key industry stakeholders and business leaders to continue promoting Canada as a reliable, stable and...



News published on 15 november 2021 at 16:05 and distributed by: